Sobre posibles medicamentos para tratar la infección por SARS-CoV-2, causante de la COVID-19: ¿hay alguna esperanza?
##plugins.themes.themeEleven.article.main##
Keywords
Virus del SARS-CoV-2, Infecciones por Coronavirus, Terapéutica, Pandemias
Resumen
Hasta el día de hoy no se cuenta con un tratamiento para los pacientes infectados con SARS-CoV-2. Se están llevando a cabo estudios en varios países y algunos han arrojado resultados prometedores; sin embargo, aún no se ha logrado identificar un tratamiento efectivo para combatir la COVID-19, una de las amenazas más serias que ha sufrido la humanidad en los últimos 100 años.
Referencias
1. Cao B, Wang Y, D, Liu W, Wang J, Fan G, et al. A trial of lopinavir–ritonavir in adults hospitalized with severe Covid-19. N Engl J Med. 2020;382:1787-99. doi:10.1056/NEJMoa2001282
2. Wu CY, Jan JT, Ma SH, Kuo CJ, Juan HF, Cheng YSE, et al. Small molecules targeting severe acute respiratory syndrome human coronavirus. PNAS. 2004;101(27):10012-7. doi:10.1073/pnas.0403596101
3. Chan JF, Yao Y, Yeung ML, Deng W, Bao L, Jia L, et al. Treatment with lopinavir/ritonavir or interferon-b1b improves outcome of MERS-CoV infection in a nonhuman primate model of common marmoset. J Infect Dis. 2015;212(12):1904-13. doi:10.1093/infdis/jiv392
4. Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Mahile M. Hydroxychloroquine and azithromycin as a treatment of COVID-19:results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020 Jul;56(1):105949. doi:10.1016/j.ijantimicag.2020.105949. Epub 2020 Mar 20.
5. Gao J, Tian Z, Yang X. Breakthrough:chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. BioScience Trends. 2020;14(1):72-3. doi:10.5582/bst.2020.01047
6. Boulware D. Post-exposure prophylaxis/preemptive therapy for SARS-coronavirus-2 (COVID-19 PEP). Minneapolis, MN:University of Minnesota;2020. Disponible en:https://clinicaltrials.gov/ct2/show/NCT04308668?cond=Coronavirus&cntry=US&state=US%3AMN&draw=2&rank=1
7. Dalgard O. Norwegian Coronavirus Disease 2019 Study (NO COVID-19). Akhershus, Norway:Akerhus University Hospital;2019. Disponible en:https://clinicaltrials.gov/ct2/show/NCT04316377?term=chloroquine+and+covid-19&draw=2&rank=3.
8. Schilling W. Chloroquine/hydroxychloroquine prevention of coronavirus disease (COVID-19) in the healthcare setting (COPCOV). Oxford, UK:University of Oxford;2020. Disponible en:https://clinicaltrials.gov/ct2/show/NCT04303507?term=chloroquine+and+covid-19&draw=2&rank=1
9. Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30:269-71.
10. Retallack H, Di Lullo E, Arias C, Knopp KA, Laurie MT, Sandoval-Espinosa C, et al. Zika virus cell tropism in the developing human brain and inhibition by azithromycin. Proc Natl Acad Sci U S A. 2016;113(50):14408-13.
11. Madrid PB, Panchal RG, Warren TK, Shurtleft AC, Endsley AN, Green CE, et al. Evaluation of Ebola virus inhibitors for drug repurposing. ACS Infect Dis. 2015;1(7):317-26. doi:10.1021/acsinfecdis.5b00030.
2. Wu CY, Jan JT, Ma SH, Kuo CJ, Juan HF, Cheng YSE, et al. Small molecules targeting severe acute respiratory syndrome human coronavirus. PNAS. 2004;101(27):10012-7. doi:10.1073/pnas.0403596101
3. Chan JF, Yao Y, Yeung ML, Deng W, Bao L, Jia L, et al. Treatment with lopinavir/ritonavir or interferon-b1b improves outcome of MERS-CoV infection in a nonhuman primate model of common marmoset. J Infect Dis. 2015;212(12):1904-13. doi:10.1093/infdis/jiv392
4. Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Mahile M. Hydroxychloroquine and azithromycin as a treatment of COVID-19:results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020 Jul;56(1):105949. doi:10.1016/j.ijantimicag.2020.105949. Epub 2020 Mar 20.
5. Gao J, Tian Z, Yang X. Breakthrough:chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. BioScience Trends. 2020;14(1):72-3. doi:10.5582/bst.2020.01047
6. Boulware D. Post-exposure prophylaxis/preemptive therapy for SARS-coronavirus-2 (COVID-19 PEP). Minneapolis, MN:University of Minnesota;2020. Disponible en:https://clinicaltrials.gov/ct2/show/NCT04308668?cond=Coronavirus&cntry=US&state=US%3AMN&draw=2&rank=1
7. Dalgard O. Norwegian Coronavirus Disease 2019 Study (NO COVID-19). Akhershus, Norway:Akerhus University Hospital;2019. Disponible en:https://clinicaltrials.gov/ct2/show/NCT04316377?term=chloroquine+and+covid-19&draw=2&rank=3.
8. Schilling W. Chloroquine/hydroxychloroquine prevention of coronavirus disease (COVID-19) in the healthcare setting (COPCOV). Oxford, UK:University of Oxford;2020. Disponible en:https://clinicaltrials.gov/ct2/show/NCT04303507?term=chloroquine+and+covid-19&draw=2&rank=1
9. Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30:269-71.
10. Retallack H, Di Lullo E, Arias C, Knopp KA, Laurie MT, Sandoval-Espinosa C, et al. Zika virus cell tropism in the developing human brain and inhibition by azithromycin. Proc Natl Acad Sci U S A. 2016;113(50):14408-13.
11. Madrid PB, Panchal RG, Warren TK, Shurtleft AC, Endsley AN, Green CE, et al. Evaluation of Ebola virus inhibitors for drug repurposing. ACS Infect Dis. 2015;1(7):317-26. doi:10.1021/acsinfecdis.5b00030.